Bacterial growth inhib 
Welcome,         Profile    Billing    Logout  
 1 Company  1 Product   1 Product   0 Diseases   2 Trials   21 News 
37 Trials

   

 
Trial + Data / EventsStatusPhNRegionInterventionsSponsorConditionsPrimary complStudy compl
meropenem/sulbactam / Generic mfg.
CASCADE, NCT05922124: Cefiderocol and Ampicillin-sulbactam vs. Colistin +/- Meropenem for Carbapenem Resistant A. Baumannii

Not yet recruiting
4
734
NA
Cefiderocol, Fetroja, Ampicillin-sulbactam, Unasyn, Colistin, Meropenem
Rambam Health Care Campus, Monaldi Hospital, Rutgers Robert Wood Johnson Medical School, Pisa University Hospital, Assaf-Harofeh Medical Center, Sheba Medical Center
Carbapenem Resistant Bacterial Infection, Acinetobacter Bacteremia, Acinetobacter Pneumonia
07/26
09/26
mSTARS, NCT05847504: mHealth-supported Skills Training for Alcohol-Related Suicidality

Not yet recruiting
N/A
10
US
mSTARS
Duke University
Alcohol Drinking, Suicide
06/25
06/25
mSTARS, NCT05847582: mHealth-supported Skills Training for Alcohol-Related Suicidality Phase 3

Not yet recruiting
N/A
35
NA
Standard inpatient psychiatric care, Inpatient Skills Training, mHealth-supported Skills Training for Alcohol-Related Suicidality (mSTARS)
Duke University
Alcohol Drinking, Suicide
06/27
08/27
Cedax (ceftibuten dihydrate) / Currax
2016-003704-31: Impact on the intestinal flora during antibiotic treatment Påverkan av tarmens normalflora i samband med antibiotikabehandling

Not yet recruiting
2
120
Europe
Ciprofloxacin, Ceftibuten, Pivmecillinam, Nitrofurantoin, trimetoprim-sulfametoxazol, Coated tablet, Ciprofloxacin, Cedax, Selexid, Furadantin, Eusaprim forte
Uppsala University, Uppsala University
Impact on the intestinal microbiota during antibiotic treatment Påverkan av tarmens normalflora i samband med antibiotikabehandling, Impact on the intestinal flora during antibiotic treatment Påverkan av tarmens normalflora i samband med antibiotikabehandling, Diseases [C] - Bacterial Infections and Mycoses [C01]
 
 
NCT05554237: A Study to Learn About the Study Medicine Called CTB+AVP in Healthy Adult People.

Completed
1
42
Europe
Placebo, Placebo comparator, PF-07612577, CTB+AVP, PF-06264006, ceftibuten (CTB)
Pfizer
Healthy
06/23
06/23
NCT06593054: To Learn How Different Forms of Study Medicine Are Taken up Into the Blood and the Effect of Food on Study Medicine in Healthy Adults

Completed
1
13
Europe
Ceftibuten, Avibactam prodrug, CTB-AVP in Tablet
Pfizer
Healthy
10/24
10/24
NCT06079775: P1, DDI & MAD PK and Safety Study of Xeruborbactam Oral Prodrug in Combo With Ceftibuten in Healthy Participants

Recruiting
1
71
RoW
Xeruborbactam Oral Prodrug, QPX7831, Ceftibuten, Xeruborbactam Oral Prodrug Placebo, QPX7831 Placebo, Ceftibuten Placebo
Qpex Biopharma, Inc., Shionogi Inc., Biomedical Advanced Research and Development Authority
Bacterial Infections
08/25
10/25
NCT06665555: Plasma and Intrapulmonary Pharmacokinetics of Ceftibuten and Ledaborbactam in Healthy Male and Female Participants 18 to ≤55 Years of Age

Completed
1
34
US
ledaborbactam etzadroxil, ceftibuten
Venatorx Pharmaceuticals, Inc., National Institute of Allergy and Infectious Diseases (NIAID)
Pharmacokinetics, Healthy Volunteers
03/25
03/25
NCT06157242: PK & Safety Study of Xeruborbactam Oral Prodrug Combined With Ceftibuten in Participants With Renal Impairment

Recruiting
1
32
US
Xeruborbactam Oral Prodrug, QPX7831, Ceftibuten
Qpex Biopharma, Inc., Shionogi Inc., Biomedical Advanced Research and Development Authority
Bacterial Infections
04/25
06/25
VNRX-7145-106, NCT06733675: Safety and PK of Ceftibuten-ledaborbactam Etzadroxil Fixed-dose Combination

Active, not recruiting
1
46
US
Ledaborbactam etzadroxil, Ceftibuten, Ceftibuten-ledaborbactam etzadroxil, Esomeprazole
Venatorx Pharmaceuticals, Inc., Biomedical Advanced Research and Development Authority
Healthy Volunteer, Pharmacokinetics, Safety, Drug-Drug Interaction (DDI), FDC
08/25
09/25
cefadroxil / Generic mfg.
COPAT, NCT05977868: Comparing Oral Versus Parenteral Antimicrobial Therapy

Terminated
4
90
US
Amoxicillin, amoxicillin-clavulanate, cefadroxil, cefpodoxime, cefalexin, ciprofloxacin, delafloxacin, doxycycline, levofloxacin, linezolid, metronidazole, moxifloxacin, rifampin, trimethoprim-sulfamethoxazole, Ampicillin, ampicillin-sulbactam, cefazolin, cefepime, ceftaroline, ceftazidime, ceftazidime-avibactam, dalbavancin, daptomycin, ertapenem, meropenem, oritavancin, oxacillin, penicillin, piperacillin-tazobactam, tigecycline, vancomycin
West Virginia University
Endovascular Infection, Bone and Joint Infection, Skin and Soft Tissue Infection, Pulmonary Infection, Gastrointestinal Infection, Genitourinary Infection
02/25
02/25
NCT04297592: Antibiotic Prophylaxis in High-Risk Arthroplasty Patients

Enrolling by invitation
4
4618
US
Cephalexin, Keflex, Doxycycline, Cefadroxil, Duricef
Mayo Clinic
Infections Joint Prosthetic, Overweight or Obesity, MSSA Colonization, MRSA, Chronic Kidney Diseases, Diabetes, Autoimmune Diseases, Inflammatory Disease, Tobacco Use
06/26
06/26
NCT04723940: Or v IV Antibiotics for Infection

Enrolling by invitation
3
308
US
Bactrim, Cefadroxil, Doxycycline Hcl, Clindamycin
Rothman Institute Orthopaedics
Joint Infection
01/23
01/23
NCT02814916 / 2014-005281-30: Dalbavancin for the Treatment of Acute Bacterial Skin and Skin Structure Infections in Children, Known or Suspected to be Caused by Susceptible Gram-positive Organisms, Including MRSA

Completed
3
199
Europe, US, RoW
Dalbavancin, Xydalba, Vancomycin, Oxacillin, Flucloxacillin, Cefadroxil, Clindamycin
AbbVie
Methicillin-Resistant Staphylococcus Aureus, Bacterial Infections, Staphylococcal Skin Infections
01/24
01/24
NCT06575192: Evaluation of the Safety and Effectiveness of ARTIA Reconstructive Tissue Matrix Breast Reconstruction (ADORA) in Adult Participants

Recruiting
3
783
US
ARTIA Reconstructive Tissue Matrix, No Intervention
AbbVie
Breast Reconstruction
12/29
12/29
DACAT, NCT06406114: Optimizing the Diagnostic Approach to Cephalosporin Allergy Testing

Not yet recruiting
2
300
US
Beta-lactam antibiotic (cefazolin, cefuroxime, cefotaxime, ceftazidime, ceftriaxone, cefepime, pre-pen, penicillin G, ampicillin, and histamine) double-blind skin testing, Culprit cephalosporin (cefazolin, ceftazidime, ceftriaxone, cefepime, cephalexin, cefaclor, cefadroxil, cefuroxime, cefpodoxime, cefdinir, or cefixime) double-blind placebo-controlled drug challenge, Similar cephalosporin (cefepime, ceftriaxone, cefaclor, cephalexin, cefixime, or cefdinir) antibiotic double-blind placebo-controlled drug challenge, Dissimilar cephalosporin (ceftriaxone or cefazolin) antibiotic double-blind placebo-controlled drug challenge, Amoxicillin double-blind placebo-controlled drug challenge
Massachusetts General Hospital, National Institute of Allergy and Infectious Diseases (NIAID)
Drug Allergy, Cephalosporin Allergy, Drug Hypersensitivity, Antibiotic Allergy, Beta Lactam Adverse Reaction, Drug-Induced Anaphylaxis, Cephalosporin Reaction
07/28
12/28
NCT06537609: A Platform Trial for Gram Negative Bloodstream Infections

Recruiting
N/A
2500
Canada, RoW
De-escalation VS No De-escalation, Oral beta-lactams VS non beta-lactams, Central vascular catheter retention VS Central vascular catheter replacement, Cephalosporin VS Carbapenem for low risk AmpC organisms, Routine follow-up blood culture VS No routine follow-up blood culture
Sunnybrook Health Sciences Centre, Canadian Institutes of Health Research (CIHR)
Gram-negative Bacteremia
04/27
04/28
BALANCE+, NCT05893147: Vanguard Phase

Completed
N/A
174
Canada
De-escalation VS No De-escalation, Oral beta-lactams VS non beta-lactams, Central vascular catheter retention VS Central vascular catheter replacement, Cephalosporin VS Carbapenem for low risk AmpC organisms, Routine follow-up blood culture VS No routine follow-up blood culture
Sunnybrook Health Sciences Centre, Canadian Institutes of Health Research (CIHR)
Gram-negative Bacteremia
07/24
08/24
OligoG CF-5/20 / AlgiPharma
2018-000378-30: A dose finding study of OligoG in patients with CF.

Not yet recruiting
2
180
Europe, RoW
OligoG CF-5/20 - 17.5 mg, OligoG CF/20 - 27.5 mg, OligoG CF/20 - 37.5 mg, Inhalation powder, hard capsule
AlgiPharma AS, H2020, AlgiPharma AS
Cystic Fibrosis, Cystic Fibrosis, Diseases [C] - Respiratory Tract Diseases [C08]
 
 
Panaecin (gallium citrate) / Aridis
NCT03669614: SAD and MAD of Inhaled AR-501 in Health Adults and P. Aeruginosa Infected Cystic Fibrosis Subjects

Recruiting
1/2
102
US
Inhaled AR-501, Inhaled Gallium Citrate, Inhaled Placebo, Control (inhaled placebo)
Aridis Pharmaceuticals, Inc.
Cystic Fibrosis
07/23
07/23
cefuroxime axetil / Generic mfg.
ChiCTR-TRC-09000301: Clinical Trial Proposal for Prospective Study of Control of Acute Exacerbation of Chronic Obstructive Pulmonary Disease(AECOPD)

Completed
4
450
 
Type III AECOPD: oral steroids (Cortisone, 30mg, QD), 5-day course; Inhaled steroids (budesonide, 2mg, BID), 5-day course; QD), 5-day course. ;Type II AECOPD: Oral steroids (Cortisone, 30mg, QD), 7-day course; Inhaled steroids (budesonide, 2mg, BID), 7-day course. ;Type I AECOPD: Respiratory quinolones (moxifloxacin, 400mg, iv drip, 2nd generation cephalosporin+macrolides (cefuroxime axetil iv drip 1.5g BID+azithromycin 0.5 iv drip QD), 5-day course.
1st Affiliated Hospital of Sun Yat-sen University; 2nd and 3rd Affiliated Hospital, Department of Statistics of School of Public Health of SYSU, Sun Yat-sen University
Acute Exacerbation of Chronic Obstructive Pulmonary Disease, classified according to Anthonisen classification
 
 
ChiCTR-OPN-17010365: Reappraisal of the safety and efficacy of cefuroxime dispersible tablet in the world market

Recruiting
4
100000
 
Cefuroxime axetil dispersible tablets
Peking Union Medical College Hospital; Peking Union Medical College Hospital, Sponsor to provide
Sensitive infections caused by bacteria
 
 
CEFURO, NCT06527560: Clinical Trial Comparing Oral Versus Intravenous Cefuroxime in Pregnant Women with Pyelonephritis

Recruiting
4
100
RoW
Cefuroxime, intravenous antibiotics + placebo Oral, Cefuroxime Axetil, oral antibiotics + placebo IV
Hospital de Clinicas de Porto Alegre
Pyelonephritis in Pregnancy
12/27
12/27
ChiCTR2200061707: A prospective, randomized, controlled, multicenter clinical study of antibiotics combined with Chinese patent medicine in the treatment of mixed vaginitis

Not yet recruiting
4
1175
 
flush vagina with HongHeFuJieXiYe ;Oral cefuroxime axetil ;Clindamycin cream vaginal application ;Clindamycin cream vaginal smear combined with HongHeFuJieXiYe vaginal rinse ;Oral cefuroxime axetil combined with HongHeFuJieXiYe vaginal rinse
Tianjin Medical University General Hospital; Tianjin Medical University General Hospital, Clinical Medicine Research Project of Tianjin Medical University General Hospital
Aerobic bacterial vaginitis combined with bacterial vaginosis
 
 
ChiCTR-OPR-15006494: Bioequivalence study of cefuroxime axetil tablet in healthy subjects

Not yet recruiting
1
24
 
Phase 1: p.o reference product (fasting state); Phase 2: p.o test product (fasting state); Phase 3: p.o reference product (postprandial state); Phase 4: p.o test product (postprandial state) ;Phase 1: p.o test product (fasting state); Phase 2: p.o reference product (fasting state); Phase 3: p.o test product (postprandial state); Phase 4: p.o reference product (postprandial state);
Union Hospital, Tongji Medical College, Huazhong University of Science and Technology; Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, Shenzhen Zhijun Pharmaceutical Co.,Ltd.
Healthy Volunteers
 
 
ChiCTR-IIR-17011314: Comparative Bioavailability of Cefuroxime Axetil tablets in Healthy Chinese Volunteers: An Open-Label, Randomized, Single-Dose, 2-Way Crossover Study

Not yet recruiting
1
64
 
RT ;TR ;RT ;TR ;RT ;TR ;RT ;TR
The First Affiliated Hospital, College of Medicine, Zhejiang University; ZHEJIANG JINGXIN PHARMACEUTICAL CO., LTD., ZHEJIANG JINGXIN PHARMACEUTICAL CO.,LTD.
infection
 
 
ChiCTR2400085260: Efficacy and safety of quadruple therapy containing tigolaxant and cefuroxime in the treatment of Helicobacter pylori infection in patients with penicillin allergy

Recruiting
1
436
 
Tegolasen 50 mg 2/day Colloidal bismuth pectin 200 mg 2/dayCefuroxime axetil 500 mg 2/dayClarithromycin 500 mg 2/day; Rabeprazole 10 mg 2 times a day Colloidal bismuth pectin 200 mg 2/dayCefuroxime axetil 500 mg 2/dayClarithromycin 500 mg 2/day
Shenzhen Second People's Hospital; Shenzhen Second People's Hospital, Shenzhen Digestive System Disease Clinical Medicine Research Center Project
Helicobacter pylori treatment
 
 
ChiCTR2100049234: Effects of cefuroxime axetil combined with Xingpi Yanger granules on the serum gastrin, motilin, and somatostatin levels in children with upper respiratory tract infection accompanied by diarrhea

Completed
N/A
124
 
routine nursing ;cefuroxime axetil dispersible tablets
Baoji Maternal and Child Health Hospital; Baoji Maternal and Child Health Hospital, None
children's upper respiratory tract infection
 
 
ChiCTR-OOC-17012584: Study on the therapeutic effect of Cefuroxime Axetil Tablets in the treatment of aerobic vaginitis

Not yet recruiting
N/A
60
 
Cefuroxime Axetil Tablets oral
Tianjin Medical University General Hospital; Tianjin Medical University General Hospital, self support
aerobic vaginitis
 
 
ChiCTR2100045855: Clinical effect of Qingre Jiedu Decoction on acute granulomatous mastitis

Recruiting
N/A
60
 
Qingre Jiedu Decoction ;Cefuroxime Axetil Tablets
Beijing Hospital of Traditional Chinese Medicine; Beijing Hospital of Traditional Chinese Medicine, Beijing Traditional Chinese Medicine Science and Technology Development Fund Project
granulomatous mastitis
 
 
NCT05577273: Does Antibiotic Prophylaxis at Urinary Catheter Removal Prevent Urinary Tract Infections

Enrolling by invitation
N/A
1000
RoW
Cefuroxime axetil (trimethoprim/sulfamethoxazole if penicillin allergy)
Omri Schwarztuch Gildor
Urologic Diseases, Urinary Tract Disease
08/23
08/23
TOL-463 / Toltec Pharma
NCT02814370: TOL-463 Phase 2 Study

Not yet recruiting
2
80
US
Boric Acid
National Institute of Allergy and Infectious Diseases (NIAID)
Vaginitis Bacterial, Vulvovaginal Candidiasis
08/17
 
bacteriophage therapy / BiomX
APT.DFO.001, NCT05177107: Bacteriophage Therapy in Patients With Diabetic Foot Osteomyelitis

Recruiting
2b
126
US
Phage Therapy, Placebo
Adaptive Phage Therapeutics, Inc., United States Department of Defense
Osteomyelitis, Diabetic Foot Osteomyelitis
04/24
12/24
ACTIVE2, NCT05269134: Bacteriophage Therapy in Patients With Prosthetic Joint Infections (PJI)

Withdrawn
2
90
US
Bacteriophage, Placebo
Adaptive Phage Therapeutics, Inc.
Prosthetic Joint Infection
07/25
07/27
NCT04287478: Bacteriophage Therapy in Patients With Urinary Tract Infections

Terminated
1/2
1
US
Bacteriophage Therapy
Adaptive Phage Therapeutics, Inc., United States Department of Defense
Urinary Tract Infection Bacterial
02/23
02/23
ACTIVE1, NCT05269121: Bacteriophage Therapy in First Time Chronic Prosthetic Joint Infections

Withdrawn
1/2
20
NA
Phage Therapy
Adaptive Phage Therapeutics, Inc.
Prosthetic Joint Infection, Bacterial Infections
11/23
11/24
NCT05453578: A Phase 1b/2 Trial of the Safety and Microbiological Activity of Bacteriophage Therapy in Cystic Fibrosis Subjects Colonized With Pseudomonas Aeruginosa

Active, not recruiting
1/2
73
US
Placebo, WRAIR-PAM-CF1
National Institute of Allergy and Infectious Diseases (NIAID)
Bacterial Disease Carrier, Cystic Fibrosis
04/25
04/25
VB-1953 / Vyome Therap
No trials found
PanOxyl PM Overnight Spot Patches (benzoyl peroxide) / Crown Labs
No trials found
Trial + Data / EventsStatusPhNRegionInterventionsSponsorConditionsPrimary complStudy compl
meropenem/sulbactam / Generic mfg.
CASCADE, NCT05922124: Cefiderocol and Ampicillin-sulbactam vs. Colistin +/- Meropenem for Carbapenem Resistant A. Baumannii

Not yet recruiting
4
734
NA
Cefiderocol, Fetroja, Ampicillin-sulbactam, Unasyn, Colistin, Meropenem
Rambam Health Care Campus, Monaldi Hospital, Rutgers Robert Wood Johnson Medical School, Pisa University Hospital, Assaf-Harofeh Medical Center, Sheba Medical Center
Carbapenem Resistant Bacterial Infection, Acinetobacter Bacteremia, Acinetobacter Pneumonia
07/26
09/26
mSTARS, NCT05847504: mHealth-supported Skills Training for Alcohol-Related Suicidality

Not yet recruiting
N/A
10
US
mSTARS
Duke University
Alcohol Drinking, Suicide
06/25
06/25
mSTARS, NCT05847582: mHealth-supported Skills Training for Alcohol-Related Suicidality Phase 3

Not yet recruiting
N/A
35
NA
Standard inpatient psychiatric care, Inpatient Skills Training, mHealth-supported Skills Training for Alcohol-Related Suicidality (mSTARS)
Duke University
Alcohol Drinking, Suicide
06/27
08/27
Cedax (ceftibuten dihydrate) / Currax
2016-003704-31: Impact on the intestinal flora during antibiotic treatment Påverkan av tarmens normalflora i samband med antibiotikabehandling

Not yet recruiting
2
120
Europe
Ciprofloxacin, Ceftibuten, Pivmecillinam, Nitrofurantoin, trimetoprim-sulfametoxazol, Coated tablet, Ciprofloxacin, Cedax, Selexid, Furadantin, Eusaprim forte
Uppsala University, Uppsala University
Impact on the intestinal microbiota during antibiotic treatment Påverkan av tarmens normalflora i samband med antibiotikabehandling, Impact on the intestinal flora during antibiotic treatment Påverkan av tarmens normalflora i samband med antibiotikabehandling, Diseases [C] - Bacterial Infections and Mycoses [C01]
 
 
NCT05554237: A Study to Learn About the Study Medicine Called CTB+AVP in Healthy Adult People.

Completed
1
42
Europe
Placebo, Placebo comparator, PF-07612577, CTB+AVP, PF-06264006, ceftibuten (CTB)
Pfizer
Healthy
06/23
06/23
NCT06593054: To Learn How Different Forms of Study Medicine Are Taken up Into the Blood and the Effect of Food on Study Medicine in Healthy Adults

Completed
1
13
Europe
Ceftibuten, Avibactam prodrug, CTB-AVP in Tablet
Pfizer
Healthy
10/24
10/24
NCT06079775: P1, DDI & MAD PK and Safety Study of Xeruborbactam Oral Prodrug in Combo With Ceftibuten in Healthy Participants

Recruiting
1
71
RoW
Xeruborbactam Oral Prodrug, QPX7831, Ceftibuten, Xeruborbactam Oral Prodrug Placebo, QPX7831 Placebo, Ceftibuten Placebo
Qpex Biopharma, Inc., Shionogi Inc., Biomedical Advanced Research and Development Authority
Bacterial Infections
08/25
10/25
NCT06665555: Plasma and Intrapulmonary Pharmacokinetics of Ceftibuten and Ledaborbactam in Healthy Male and Female Participants 18 to ≤55 Years of Age

Completed
1
34
US
ledaborbactam etzadroxil, ceftibuten
Venatorx Pharmaceuticals, Inc., National Institute of Allergy and Infectious Diseases (NIAID)
Pharmacokinetics, Healthy Volunteers
03/25
03/25
NCT06157242: PK & Safety Study of Xeruborbactam Oral Prodrug Combined With Ceftibuten in Participants With Renal Impairment

Recruiting
1
32
US
Xeruborbactam Oral Prodrug, QPX7831, Ceftibuten
Qpex Biopharma, Inc., Shionogi Inc., Biomedical Advanced Research and Development Authority
Bacterial Infections
04/25
06/25
VNRX-7145-106, NCT06733675: Safety and PK of Ceftibuten-ledaborbactam Etzadroxil Fixed-dose Combination

Active, not recruiting
1
46
US
Ledaborbactam etzadroxil, Ceftibuten, Ceftibuten-ledaborbactam etzadroxil, Esomeprazole
Venatorx Pharmaceuticals, Inc., Biomedical Advanced Research and Development Authority
Healthy Volunteer, Pharmacokinetics, Safety, Drug-Drug Interaction (DDI), FDC
08/25
09/25
cefadroxil / Generic mfg.
COPAT, NCT05977868: Comparing Oral Versus Parenteral Antimicrobial Therapy

Terminated
4
90
US
Amoxicillin, amoxicillin-clavulanate, cefadroxil, cefpodoxime, cefalexin, ciprofloxacin, delafloxacin, doxycycline, levofloxacin, linezolid, metronidazole, moxifloxacin, rifampin, trimethoprim-sulfamethoxazole, Ampicillin, ampicillin-sulbactam, cefazolin, cefepime, ceftaroline, ceftazidime, ceftazidime-avibactam, dalbavancin, daptomycin, ertapenem, meropenem, oritavancin, oxacillin, penicillin, piperacillin-tazobactam, tigecycline, vancomycin
West Virginia University
Endovascular Infection, Bone and Joint Infection, Skin and Soft Tissue Infection, Pulmonary Infection, Gastrointestinal Infection, Genitourinary Infection
02/25
02/25
NCT04297592: Antibiotic Prophylaxis in High-Risk Arthroplasty Patients

Enrolling by invitation
4
4618
US
Cephalexin, Keflex, Doxycycline, Cefadroxil, Duricef
Mayo Clinic
Infections Joint Prosthetic, Overweight or Obesity, MSSA Colonization, MRSA, Chronic Kidney Diseases, Diabetes, Autoimmune Diseases, Inflammatory Disease, Tobacco Use
06/26
06/26
NCT04723940: Or v IV Antibiotics for Infection

Enrolling by invitation
3
308
US
Bactrim, Cefadroxil, Doxycycline Hcl, Clindamycin
Rothman Institute Orthopaedics
Joint Infection
01/23
01/23
NCT02814916 / 2014-005281-30: Dalbavancin for the Treatment of Acute Bacterial Skin and Skin Structure Infections in Children, Known or Suspected to be Caused by Susceptible Gram-positive Organisms, Including MRSA

Completed
3
199
Europe, US, RoW
Dalbavancin, Xydalba, Vancomycin, Oxacillin, Flucloxacillin, Cefadroxil, Clindamycin
AbbVie
Methicillin-Resistant Staphylococcus Aureus, Bacterial Infections, Staphylococcal Skin Infections
01/24
01/24
NCT06575192: Evaluation of the Safety and Effectiveness of ARTIA Reconstructive Tissue Matrix Breast Reconstruction (ADORA) in Adult Participants

Recruiting
3
783
US
ARTIA Reconstructive Tissue Matrix, No Intervention
AbbVie
Breast Reconstruction
12/29
12/29
DACAT, NCT06406114: Optimizing the Diagnostic Approach to Cephalosporin Allergy Testing

Not yet recruiting
2
300
US
Beta-lactam antibiotic (cefazolin, cefuroxime, cefotaxime, ceftazidime, ceftriaxone, cefepime, pre-pen, penicillin G, ampicillin, and histamine) double-blind skin testing, Culprit cephalosporin (cefazolin, ceftazidime, ceftriaxone, cefepime, cephalexin, cefaclor, cefadroxil, cefuroxime, cefpodoxime, cefdinir, or cefixime) double-blind placebo-controlled drug challenge, Similar cephalosporin (cefepime, ceftriaxone, cefaclor, cephalexin, cefixime, or cefdinir) antibiotic double-blind placebo-controlled drug challenge, Dissimilar cephalosporin (ceftriaxone or cefazolin) antibiotic double-blind placebo-controlled drug challenge, Amoxicillin double-blind placebo-controlled drug challenge
Massachusetts General Hospital, National Institute of Allergy and Infectious Diseases (NIAID)
Drug Allergy, Cephalosporin Allergy, Drug Hypersensitivity, Antibiotic Allergy, Beta Lactam Adverse Reaction, Drug-Induced Anaphylaxis, Cephalosporin Reaction
07/28
12/28
NCT06537609: A Platform Trial for Gram Negative Bloodstream Infections

Recruiting
N/A
2500
Canada, RoW
De-escalation VS No De-escalation, Oral beta-lactams VS non beta-lactams, Central vascular catheter retention VS Central vascular catheter replacement, Cephalosporin VS Carbapenem for low risk AmpC organisms, Routine follow-up blood culture VS No routine follow-up blood culture
Sunnybrook Health Sciences Centre, Canadian Institutes of Health Research (CIHR)
Gram-negative Bacteremia
04/27
04/28
BALANCE+, NCT05893147: Vanguard Phase

Completed
N/A
174
Canada
De-escalation VS No De-escalation, Oral beta-lactams VS non beta-lactams, Central vascular catheter retention VS Central vascular catheter replacement, Cephalosporin VS Carbapenem for low risk AmpC organisms, Routine follow-up blood culture VS No routine follow-up blood culture
Sunnybrook Health Sciences Centre, Canadian Institutes of Health Research (CIHR)
Gram-negative Bacteremia
07/24
08/24
OligoG CF-5/20 / AlgiPharma
2018-000378-30: A dose finding study of OligoG in patients with CF.

Not yet recruiting
2
180
Europe, RoW
OligoG CF-5/20 - 17.5 mg, OligoG CF/20 - 27.5 mg, OligoG CF/20 - 37.5 mg, Inhalation powder, hard capsule
AlgiPharma AS, H2020, AlgiPharma AS
Cystic Fibrosis, Cystic Fibrosis, Diseases [C] - Respiratory Tract Diseases [C08]
 
 
Panaecin (gallium citrate) / Aridis
NCT03669614: SAD and MAD of Inhaled AR-501 in Health Adults and P. Aeruginosa Infected Cystic Fibrosis Subjects

Recruiting
1/2
102
US
Inhaled AR-501, Inhaled Gallium Citrate, Inhaled Placebo, Control (inhaled placebo)
Aridis Pharmaceuticals, Inc.
Cystic Fibrosis
07/23
07/23
cefuroxime axetil / Generic mfg.
ChiCTR-TRC-09000301: Clinical Trial Proposal for Prospective Study of Control of Acute Exacerbation of Chronic Obstructive Pulmonary Disease(AECOPD)

Completed
4
450
 
Type III AECOPD: oral steroids (Cortisone, 30mg, QD), 5-day course; Inhaled steroids (budesonide, 2mg, BID), 5-day course; QD), 5-day course. ;Type II AECOPD: Oral steroids (Cortisone, 30mg, QD), 7-day course; Inhaled steroids (budesonide, 2mg, BID), 7-day course. ;Type I AECOPD: Respiratory quinolones (moxifloxacin, 400mg, iv drip, 2nd generation cephalosporin+macrolides (cefuroxime axetil iv drip 1.5g BID+azithromycin 0.5 iv drip QD), 5-day course.
1st Affiliated Hospital of Sun Yat-sen University; 2nd and 3rd Affiliated Hospital, Department of Statistics of School of Public Health of SYSU, Sun Yat-sen University
Acute Exacerbation of Chronic Obstructive Pulmonary Disease, classified according to Anthonisen classification
 
 
ChiCTR-OPN-17010365: Reappraisal of the safety and efficacy of cefuroxime dispersible tablet in the world market

Recruiting
4
100000
 
Cefuroxime axetil dispersible tablets
Peking Union Medical College Hospital; Peking Union Medical College Hospital, Sponsor to provide
Sensitive infections caused by bacteria
 
 
CEFURO, NCT06527560: Clinical Trial Comparing Oral Versus Intravenous Cefuroxime in Pregnant Women with Pyelonephritis

Recruiting
4
100
RoW
Cefuroxime, intravenous antibiotics + placebo Oral, Cefuroxime Axetil, oral antibiotics + placebo IV
Hospital de Clinicas de Porto Alegre
Pyelonephritis in Pregnancy
12/27
12/27
ChiCTR2200061707: A prospective, randomized, controlled, multicenter clinical study of antibiotics combined with Chinese patent medicine in the treatment of mixed vaginitis

Not yet recruiting
4
1175
 
flush vagina with HongHeFuJieXiYe ;Oral cefuroxime axetil ;Clindamycin cream vaginal application ;Clindamycin cream vaginal smear combined with HongHeFuJieXiYe vaginal rinse ;Oral cefuroxime axetil combined with HongHeFuJieXiYe vaginal rinse
Tianjin Medical University General Hospital; Tianjin Medical University General Hospital, Clinical Medicine Research Project of Tianjin Medical University General Hospital
Aerobic bacterial vaginitis combined with bacterial vaginosis
 
 
ChiCTR-OPR-15006494: Bioequivalence study of cefuroxime axetil tablet in healthy subjects

Not yet recruiting
1
24
 
Phase 1: p.o reference product (fasting state); Phase 2: p.o test product (fasting state); Phase 3: p.o reference product (postprandial state); Phase 4: p.o test product (postprandial state) ;Phase 1: p.o test product (fasting state); Phase 2: p.o reference product (fasting state); Phase 3: p.o test product (postprandial state); Phase 4: p.o reference product (postprandial state);
Union Hospital, Tongji Medical College, Huazhong University of Science and Technology; Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, Shenzhen Zhijun Pharmaceutical Co.,Ltd.
Healthy Volunteers
 
 
ChiCTR-IIR-17011314: Comparative Bioavailability of Cefuroxime Axetil tablets in Healthy Chinese Volunteers: An Open-Label, Randomized, Single-Dose, 2-Way Crossover Study

Not yet recruiting
1
64
 
RT ;TR ;RT ;TR ;RT ;TR ;RT ;TR
The First Affiliated Hospital, College of Medicine, Zhejiang University; ZHEJIANG JINGXIN PHARMACEUTICAL CO., LTD., ZHEJIANG JINGXIN PHARMACEUTICAL CO.,LTD.
infection
 
 
ChiCTR2400085260: Efficacy and safety of quadruple therapy containing tigolaxant and cefuroxime in the treatment of Helicobacter pylori infection in patients with penicillin allergy

Recruiting
1
436
 
Tegolasen 50 mg 2/day Colloidal bismuth pectin 200 mg 2/dayCefuroxime axetil 500 mg 2/dayClarithromycin 500 mg 2/day; Rabeprazole 10 mg 2 times a day Colloidal bismuth pectin 200 mg 2/dayCefuroxime axetil 500 mg 2/dayClarithromycin 500 mg 2/day
Shenzhen Second People's Hospital; Shenzhen Second People's Hospital, Shenzhen Digestive System Disease Clinical Medicine Research Center Project
Helicobacter pylori treatment
 
 
ChiCTR2100049234: Effects of cefuroxime axetil combined with Xingpi Yanger granules on the serum gastrin, motilin, and somatostatin levels in children with upper respiratory tract infection accompanied by diarrhea

Completed
N/A
124
 
routine nursing ;cefuroxime axetil dispersible tablets
Baoji Maternal and Child Health Hospital; Baoji Maternal and Child Health Hospital, None
children's upper respiratory tract infection
 
 
ChiCTR-OOC-17012584: Study on the therapeutic effect of Cefuroxime Axetil Tablets in the treatment of aerobic vaginitis

Not yet recruiting
N/A
60
 
Cefuroxime Axetil Tablets oral
Tianjin Medical University General Hospital; Tianjin Medical University General Hospital, self support
aerobic vaginitis
 
 
ChiCTR2100045855: Clinical effect of Qingre Jiedu Decoction on acute granulomatous mastitis

Recruiting
N/A
60
 
Qingre Jiedu Decoction ;Cefuroxime Axetil Tablets
Beijing Hospital of Traditional Chinese Medicine; Beijing Hospital of Traditional Chinese Medicine, Beijing Traditional Chinese Medicine Science and Technology Development Fund Project
granulomatous mastitis
 
 
NCT05577273: Does Antibiotic Prophylaxis at Urinary Catheter Removal Prevent Urinary Tract Infections

Enrolling by invitation
N/A
1000
RoW
Cefuroxime axetil (trimethoprim/sulfamethoxazole if penicillin allergy)
Omri Schwarztuch Gildor
Urologic Diseases, Urinary Tract Disease
08/23
08/23
TOL-463 / Toltec Pharma
NCT02814370: TOL-463 Phase 2 Study

Not yet recruiting
2
80
US
Boric Acid
National Institute of Allergy and Infectious Diseases (NIAID)
Vaginitis Bacterial, Vulvovaginal Candidiasis
08/17
 
bacteriophage therapy / BiomX
APT.DFO.001, NCT05177107: Bacteriophage Therapy in Patients With Diabetic Foot Osteomyelitis

Recruiting
2b
126
US
Phage Therapy, Placebo
Adaptive Phage Therapeutics, Inc., United States Department of Defense
Osteomyelitis, Diabetic Foot Osteomyelitis
04/24
12/24
ACTIVE2, NCT05269134: Bacteriophage Therapy in Patients With Prosthetic Joint Infections (PJI)

Withdrawn
2
90
US
Bacteriophage, Placebo
Adaptive Phage Therapeutics, Inc.
Prosthetic Joint Infection
07/25
07/27
NCT04287478: Bacteriophage Therapy in Patients With Urinary Tract Infections

Terminated
1/2
1
US
Bacteriophage Therapy
Adaptive Phage Therapeutics, Inc., United States Department of Defense
Urinary Tract Infection Bacterial
02/23
02/23
ACTIVE1, NCT05269121: Bacteriophage Therapy in First Time Chronic Prosthetic Joint Infections

Withdrawn
1/2
20
NA
Phage Therapy
Adaptive Phage Therapeutics, Inc.
Prosthetic Joint Infection, Bacterial Infections
11/23
11/24
NCT05453578: A Phase 1b/2 Trial of the Safety and Microbiological Activity of Bacteriophage Therapy in Cystic Fibrosis Subjects Colonized With Pseudomonas Aeruginosa

Active, not recruiting
1/2
73
US
Placebo, WRAIR-PAM-CF1
National Institute of Allergy and Infectious Diseases (NIAID)
Bacterial Disease Carrier, Cystic Fibrosis
04/25
04/25
VB-1953 / Vyome Therap
No trials found
PanOxyl PM Overnight Spot Patches (benzoyl peroxide) / Crown Labs
No trials found

Download Options